Comparison of analytical performances between clot waveform analysis and FibWave in edoxaban‐treated patients and healthy controls
Abstract Introduction The activated partial thromboplastin time (aPTT) and the prothrombin time (PT) are widely available coagulation parameters which are however poor predictors of the anticoagulant effect of direct oral anticoagulants (DOACs). Some coagulometers use the clot waveform analysis (CWA...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-10-01
|
| Series: | Research and Practice in Thrombosis and Haemostasis |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/rth2.12804 |
| _version_ | 1797757347471294464 |
|---|---|
| author | Jonathan Evrard Romain Siriez Céline Bouvy Julien Favresse Halil Yildiz Philippe Hainaut François Mullier Jean‐Michel Dogné Jonathan Douxfils |
| author_facet | Jonathan Evrard Romain Siriez Céline Bouvy Julien Favresse Halil Yildiz Philippe Hainaut François Mullier Jean‐Michel Dogné Jonathan Douxfils |
| author_sort | Jonathan Evrard |
| collection | DOAJ |
| description | Abstract Introduction The activated partial thromboplastin time (aPTT) and the prothrombin time (PT) are widely available coagulation parameters which are however poor predictors of the anticoagulant effect of direct oral anticoagulants (DOACs). Some coagulometers use the clot waveform analysis (CWA) to assess the clotting time but mainly based on a unique parameter. The improvement of these methodologies and the evaluation of the other waveform parameters may increase the sensitivity to DOACs. Objectives To assess the performance of an improved clot waveform an method (i.e. FibWave) to detect the impact of edoxaban on the coagulation and the fibrinolytic systems. Methods Seventy‐one samples from patients treated with edoxaban collected at minimum concentration (CTROUGH) and/or maximum concentration (CMAX), and 45 control samples were included. The aPTT‐ and PT‐based CWA as well as the FibIn, FibEx, and FibLysis methodologies of the FibWave were implemented and performed on an ACL‐TOP 700. Results PT and FibEx clotting time were strongly correlated to edoxaban concentration (Pearson r = 0.80 and 0.89, respectively). The FibEx clotting time allowed a better discrimination for samples with 30 and 50 ng/ml of edoxaban compared to PT (cutoffs of 96.5 and 114.2 s for the FibEx versus a unique cutoff of 13.1 s for the PT). The fibrinolytic process was impaired in the presence of edoxaban in a dose‐dependent manner. Conclusion FibEx is more sensitive than aPTT‐ and PT‐based CWA for the detection of the clinically relevant anticoagulant level of edoxaban. |
| first_indexed | 2024-03-12T18:14:32Z |
| format | Article |
| id | doaj.art-9d121dd28dea4655bd8d0228fc63adb6 |
| institution | Directory Open Access Journal |
| issn | 2475-0379 |
| language | English |
| last_indexed | 2024-03-12T18:14:32Z |
| publishDate | 2022-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Research and Practice in Thrombosis and Haemostasis |
| spelling | doaj.art-9d121dd28dea4655bd8d0228fc63adb62023-08-02T09:11:54ZengElsevierResearch and Practice in Thrombosis and Haemostasis2475-03792022-10-0167n/an/a10.1002/rth2.12804Comparison of analytical performances between clot waveform analysis and FibWave in edoxaban‐treated patients and healthy controlsJonathan Evrard0Romain Siriez1Céline Bouvy2Julien Favresse3Halil Yildiz4Philippe Hainaut5François Mullier6Jean‐Michel Dogné7Jonathan Douxfils8Department of Pharmacy Université de Namur, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS) Namur BelgiumDepartment of Pharmacy Université de Namur, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS) Namur BelgiumQualiblood s.a. Namur BelgiumDepartment of Pharmacy Université de Namur, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS) Namur BelgiumDepartment of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint‐Luc Université Catholique de Louvain Brussels BelgiumDepartment of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint‐Luc Université Catholique de Louvain Brussels BelgiumHematology Laboratory Université Catholique de Louvain, CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS) Yvoir BelgiumDepartment of Pharmacy Université de Namur, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS) Namur BelgiumDepartment of Pharmacy Université de Namur, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS) Namur BelgiumAbstract Introduction The activated partial thromboplastin time (aPTT) and the prothrombin time (PT) are widely available coagulation parameters which are however poor predictors of the anticoagulant effect of direct oral anticoagulants (DOACs). Some coagulometers use the clot waveform analysis (CWA) to assess the clotting time but mainly based on a unique parameter. The improvement of these methodologies and the evaluation of the other waveform parameters may increase the sensitivity to DOACs. Objectives To assess the performance of an improved clot waveform an method (i.e. FibWave) to detect the impact of edoxaban on the coagulation and the fibrinolytic systems. Methods Seventy‐one samples from patients treated with edoxaban collected at minimum concentration (CTROUGH) and/or maximum concentration (CMAX), and 45 control samples were included. The aPTT‐ and PT‐based CWA as well as the FibIn, FibEx, and FibLysis methodologies of the FibWave were implemented and performed on an ACL‐TOP 700. Results PT and FibEx clotting time were strongly correlated to edoxaban concentration (Pearson r = 0.80 and 0.89, respectively). The FibEx clotting time allowed a better discrimination for samples with 30 and 50 ng/ml of edoxaban compared to PT (cutoffs of 96.5 and 114.2 s for the FibEx versus a unique cutoff of 13.1 s for the PT). The fibrinolytic process was impaired in the presence of edoxaban in a dose‐dependent manner. Conclusion FibEx is more sensitive than aPTT‐ and PT‐based CWA for the detection of the clinically relevant anticoagulant level of edoxaban.https://doi.org/10.1002/rth2.12804activated partial thromboplastin timeanticoagulantsclot waveform analysisedoxabanfibrinfibrinolysis |
| spellingShingle | Jonathan Evrard Romain Siriez Céline Bouvy Julien Favresse Halil Yildiz Philippe Hainaut François Mullier Jean‐Michel Dogné Jonathan Douxfils Comparison of analytical performances between clot waveform analysis and FibWave in edoxaban‐treated patients and healthy controls Research and Practice in Thrombosis and Haemostasis activated partial thromboplastin time anticoagulants clot waveform analysis edoxaban fibrin fibrinolysis |
| title | Comparison of analytical performances between clot waveform analysis and FibWave in edoxaban‐treated patients and healthy controls |
| title_full | Comparison of analytical performances between clot waveform analysis and FibWave in edoxaban‐treated patients and healthy controls |
| title_fullStr | Comparison of analytical performances between clot waveform analysis and FibWave in edoxaban‐treated patients and healthy controls |
| title_full_unstemmed | Comparison of analytical performances between clot waveform analysis and FibWave in edoxaban‐treated patients and healthy controls |
| title_short | Comparison of analytical performances between clot waveform analysis and FibWave in edoxaban‐treated patients and healthy controls |
| title_sort | comparison of analytical performances between clot waveform analysis and fibwave in edoxaban treated patients and healthy controls |
| topic | activated partial thromboplastin time anticoagulants clot waveform analysis edoxaban fibrin fibrinolysis |
| url | https://doi.org/10.1002/rth2.12804 |
| work_keys_str_mv | AT jonathanevrard comparisonofanalyticalperformancesbetweenclotwaveformanalysisandfibwaveinedoxabantreatedpatientsandhealthycontrols AT romainsiriez comparisonofanalyticalperformancesbetweenclotwaveformanalysisandfibwaveinedoxabantreatedpatientsandhealthycontrols AT celinebouvy comparisonofanalyticalperformancesbetweenclotwaveformanalysisandfibwaveinedoxabantreatedpatientsandhealthycontrols AT julienfavresse comparisonofanalyticalperformancesbetweenclotwaveformanalysisandfibwaveinedoxabantreatedpatientsandhealthycontrols AT halilyildiz comparisonofanalyticalperformancesbetweenclotwaveformanalysisandfibwaveinedoxabantreatedpatientsandhealthycontrols AT philippehainaut comparisonofanalyticalperformancesbetweenclotwaveformanalysisandfibwaveinedoxabantreatedpatientsandhealthycontrols AT francoismullier comparisonofanalyticalperformancesbetweenclotwaveformanalysisandfibwaveinedoxabantreatedpatientsandhealthycontrols AT jeanmicheldogne comparisonofanalyticalperformancesbetweenclotwaveformanalysisandfibwaveinedoxabantreatedpatientsandhealthycontrols AT jonathandouxfils comparisonofanalyticalperformancesbetweenclotwaveformanalysisandfibwaveinedoxabantreatedpatientsandhealthycontrols |